20242023202220212020

2024 Issuances

• [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
  November 8, 2024
• [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir
  October 21, 2024
• HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
  September 25, 2024
• HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
  September 25, 2024
• HTA Council Recommendation on Calcium Hydroxide 80% + Clinoptilolite 20% (Kiti-kitiX) Larvicide
  September 10, 2024
• [Advisory] Release of HTA Topic Prioritization List 2024 – Cycle 2 Topics that will proceed to Topic Assessment
  May 24, 2024
• EXTENSION OF THE STAKEHOLDER APPEALS PERIOD FOR THE 2024 PROVISIONAL LIST OF PRIORITY HTA TOPICS
  April 24, 2024
• [Advisory] Release of the Provisional TP List (April 2024)
  April 17, 2024

2023 Issuances

• [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of DOACs for Nonvalvular Atrial Fibrillation
  March 24, 2023
• [Announcement] HTA Council Releases Its Preliminary Recommendation on the Non-Financing of Cerebrolysin for Post Ischemic Stroke
  March 24, 2023
• HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe
  March 14, 2023
• HTAC Guidance: PNF Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe
  March 14, 2023
• [Announcement] Ceremonial Turnover of HTA Implementation from the Department of Health to the Department of Science and Technology
  March 9, 2023
• [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus
  March 8, 2023
• [Department Circular No. 2023-0059] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Deferasirox 90 mg and 180 mg Film-Coated Tablet (FCT) for Chronic Iron Overload due to Repetitive Blood Transfusions in Patients 2 Years Old and Above in the Philippine National Formulary (PNF)
  February 13, 2023
• [Department Circular No. 2023-0061] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe for the Treatment of Neutropenia in Patients Undergoing Bone Marrow Transplantation and Patients Receiving Myelosuppressive Cancer Chemotherapy in the Philippine National Formulary (PNF)
  February 13, 2023
• [DC No. 2023-0060] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe for the Management of Chemotherapy-Induced Anemia in Patients with Non-Myeloid Disease in the Philippine National Formulary (PNF)
  February 13, 2023

2022 Issuances

• [Advisory] Extension of the Call for Nominations to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members until 27 January 2023
  December 22, 2022
• [Department Circular No. 2022 – 0625] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Abiraterone Acetate and Non-Inclusion of Enzalutamide for Individuals with Metastatic Castration-Resistant Prostate Cancer in the Philippine National Formulary (PNF)
  December 15, 2022
• [Department Memorandum No. 2022 – 0545] Interim Guidelines on the Process and Methods for the Selection of Medical Devices for Inclusion in the Philippine Essential Medical Device List (PEMDL)
  December 14, 2022
• [Advisory] Publication of the Guidelines on the Application of the Philippine Social Values on the Health Technology Assessment (HTA)
  December 13, 2022
• [Advisory] Extension of the Call for Nominations to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members until 07 December 2022
  November 14, 2022
• [Department Personnel Order No. 2022 – 3735] Appointment of the Health Technology Assessment Council Core and Subcommittees
  November 10, 2022
• [Department Circular No. 2022 – 0584] Amendment to the Department Circular 2022-0254 dated 05 April 2022 titled, “Updates on the HTAC Processing of Minor Inclusion”
  November 9, 2022
• [Department Circular No. 2022 – 0580] Release of the Final Priority List of HTA Topics for 2022 That Will Proceed to Topic Assessment
  November 7, 2022
• [Department Circular No. 2022 – 0560] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)
  October 28, 2022
• [Department Personnel Order No. 2022 – 3725] Appointment of the Health Technology Assessment Council Core and Subcommittees
  October 20, 2022
• [Department Circular No. 2022 – 0537] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Insulin Glargine and Non inclusion of Insulin Detemir for Patients with Type 1 or Type 2 Diabetes Mellitus in the Philippine National Formulary (PNF)
  October 14, 2022
• HTAC Preliminary Recommendation on Abiraterone Acetate (250mg Tablet) and Enzalutamide (40mg Soft Gel Capsule)
  October 4, 2022
• [Department Circular No. 2022 – 0291] Amendment to the Department Circular 2022-0291 “Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary”
  September 27, 2022
• [Department Circular No. 2022 – 0491] Nomination to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members
  September 23, 2022
• [Department Circular No. 2022 – 0486] Health Technology Assessment Council (HTAC) Recommendation for the Non-inclusion of Eribulin as Second-line Treatment of Metastatic Soft Tissue sarcoma (mSTS) the Philippine National Formulary (PNF)
  September 20, 2022
• [Advisory] Draft Department Memorandum on the Methodology of PEMDL Draft Interim Guidelines on the Process and Methods for the Selection of Medical Devices for Inclusion in the Philippine Essential Medical Device List (PEMDL) for Comments until 21 September 2022
  September 14, 2022
• HTAC Preliminary Recommendation for Government Financing of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease
  September 7, 2022
• [Department Memorandum No. 2022- 0379] Updated Checklist of Requirements for the Health Technology Assessment of COVID-19 Health Technologies to be referred by the Disease Prevention and Control Bureau (DPCB) and National Vaccine Operations Center (NVOC)
  September 2, 2022
• [Department Circular No. 2022- 0400] Change in the Generic Name of “Nicotine Polacrilex Medicated Chewing Gum” in the Philippine National Formulary (PNF) to “Nicotine”
  August 4, 2022
• Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF
  July 26, 2022
• Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF
  June 15, 2022
• [Department Personnel No. 2022- 2048] Creation of a Screening Committee for the Appointment of Health Technology Assessment Committee (HTAC) Members
  June 13, 2022
• [Department Circular No. 2022- 0288] Nomination to the Health Technology Assessment Council (HTAC) Social Anthropologist Core Committee Member
  June 10, 2022
• [Department Circular No. 2022- 0291] Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary
  June 6, 2022
• [Department Circular No. 2022- 0257] Changes to the Topic Nomination and Appeals Processes of the Philippine HTA Process Guide
  May 27, 2022
• [Department Circular No. 2022- 0254] Updates on the HTAC processing of Minor Inclusion Application
  May 20, 2022
• [Department Personnel No. 2022- 2780 – A] Amendment to the Department Personnel Order No. 2021-2780 Entitled “Creation of the Pool of Clinical Experts for Consultation on the Evaluation of Assessment Topics” to Include Expert Advisory Committee as Additional Experts
  May 17, 2022
• [Department Personnel Order No. 2022- 1245] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Drugs
  May 10, 2022
• Preliminary Recommendation for the Inclusion of Potassium Citrate 1620 mg (15 mEq) Tablet in the PNF
  April 13, 2022
• [Department Personnel Order No. 2022- 1102] Authority for Select Department of Health (DOH) Personnel to conduct a Hybrid Workshop on the Development of Guidelines in the Creation of the Philippine Essential Medical Device List (PEMDL) on April 22, 2022 in Metro Manila,
  April 7, 2022
• [Department Circular No. 2022- 0183] Opening of the 2022 Call for topic nomination
  April 1, 2022
• [Department Circular No. 2022- 0164] Health Technology Assessment Council (HTAC) Recommendation for reinclusion of vasopressin 20 iU/ml (IM/IV) in the Philippine National Formulary
  March 23, 2022
• Preliminary Recommendation for the Inclusion of Rituximab 1400 mg/11.7 mL Solution for Subcutaneous (SC) Injection for the Treatment of Non-Hodgkin’s Lymphoma
  March 4, 2022
• Preliminary Recommendation for the Inclusion of Vasopressin 20 IU/mL (IM/IV)
  February 11, 2022
• [Department Circular No. 2022- 0074] Nomination to the Health Technology Assessment Council (HTAC) Subcommittee on Drugs
  February 9, 2022
• [Department Circular No. 2022- 0015] Health Technology Assessment Council (HTAC) Recommendation to Include Sambong 250mg Tablet in the Philippine National Formulary
  January 21, 2022
• Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
  January 20, 2022
• [Department Personnel Order No. 2021-3184] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Preventive and Promotive Health
  January 5, 2022

2021 Issuances

• Preliminary Recommendation for the Inclusion of Sambong 250mg Tablets as Anti-Urolithiasis
  December 23, 2021
• Preliminary Recommendation on Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP)
  December 16, 2021
• [Department Personnel Order No. 2021-2780] Creation of Pool of Clinical Experts for Consultation on the Evaluation of Assessment Topics
  December 10, 2021
• [Department Circular No. 2021- 0471] Nomination to the Health Technology Assessment Council (HTAC) Subcommittee on Preventive and Promotive Health
  October 22, 2021
• [Department Circular No. 2021- 0468] Health Technology Assessment Council (HTAC) Recommendations on COVID-19 Vaccination of the Pediatric Population
  October 22, 2021
• [Signed by Secretary of Health] HTAC Recommendations on Booster and Additional Dose
  October 21, 2021
• [Signed by Secretary of Health] HTAC Interim Recommendations on Pediatric Vaccination for 2022 COVID-19 Vaccine Implementation
  October 15, 2021
• [Signed by Secretary of Health] September Updates on 2021 HTAC Recommendations for Rapid Antigen Tests
  October 12, 2021
• [Department Circular No. 2021- 0423] Inclusion of Dolutegravir (DTG) in the Philippine National Formulary (PNF)
  September 28, 2021
• [Signed by Secretary of Health] Letter of Endorsement for Dolutegravir for the Second-line Treatment for Treatment Experienced Adolescents and Adults Living with HIV
  September 21, 2021
• [Department Circular No. 2021- 0410] Inclusion of Two-Dose Inactivated Polio Vaccine (IPV) in the Philippine National Formulary (PNF)
  September 20, 2021
• [Department Circular No. 2021- 0400] Inclusion of Tenofovir/Lamivudine/Dolutegravir (TLD) in the Philippine National Formulary (PNF)
  September 10, 2021
• [Department Circular No. 2021- 0376] Interim Requirements for the Health technology Assessment (HTA) of Medical Devices
  September 3, 2021
• [Department Memorandum No. 2021- 0367] Health Technology Assessment Council’s (HTAC) Updated Recommendation on COVID-19 Vaccine Sinovac
  August 27, 2021
• Preliminary Recommendation on Dolutegravir (DTG)
  August 27, 2021
• [Department Circular No. 2021- 0337] Rescheduling of the Opening HTA Topic Nominations to March 2022
  August 17, 2021
• [Department Circular No. 2021- 0331] The Health Technology Assessment Council (HTAC) Releases Its Updated Evidence Summaries for COVID-19 Vaccine Assessments
  August 17, 2021
• MEMORANDUM- Request for Comments on Evaluation Framework for COVID-19 Vaccines (Version 2)
  August 16, 2021
• [Department Circular No. 2021- 0348] Coresia Vaccine Certificate Survey for Key Stakeholders
  August 10, 2021
• Preliminary Recommendation on Tenofovir/Lamivudine/Dolutegravir (TLD)
  August 9, 2021
• [Department Memorandum No. 2021- 0317] Non-inclusion of Pazopanib as a Second-line Treatment for Metastatic Soft Tissue (mSTS) Sarcoma in the Philippine National Formulary (PNF)
  July 21, 2021
• [Department Circular No. 2021- 0273] HTAC Issuance on Acceptance and processing of Health Technologies under Monitored Release with Phase IV Trial Data
  July 20, 2021
• Preliminary Recommendation on Two-Dose Inactivated Polio Vaccine (IPV)
  July 13, 2021
• [Department Memorandum No. 2021- 0294] Non-inclusion of Lapatinib in the Philippine National Formulary
  July 5, 2021
• [Department Memorandum No. 2021- 0264] Health Technology Assessment Council’s (HTAC) Recommendation on COVID-19 Vaccine Moderna
  June 9, 2021
• [Department Memorandum No. 2021- 0252] Health Technology Assessment Council’s (HTAC) Recommendations on RT-PCR and Rapid Antigen Testing for COVID-19
  June 1, 2021
• Preliminary Recommendation on Lapatinib
  May 31, 2021
• [Department Memorandum No. 2021- 0242] Inclusion of Nicotine Replacement Therapy (NRT) and Varenicline in the Primary Care Formulary
  May 27, 2021
• [Department Memorandum No. 2021- 0227] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 Health Technologies
  May 17, 2021
• [Department Memorandum No. 2021- 0199] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 Health Technologies
  April 23, 2021
• [Department Memorandum No. 2021- 0158] Inclusion of 0.1% Sodium Hyaluronate (15 ml) and 2.5% Peritoneal Dialysis Solution (2L and 5L) in the Philippine National Formulary
  April 5, 2021
• [Department Circular No. 2021- 0079] Health Technology Assessment Council’s (HTAC) Recommendations on health technologies requiring Full Certificate of Registration (CPR) from the Food and Drug Administration
  March 5, 2021
• [Department Memorandum No. 2021- 0075] Compliance to Dissemination of the Recommendations of the Health Technology Assessment Council (HTAC)
  February 26, 2021
• [Department Memorandum No. 2021- 0097] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 Health Technologies
  February 26, 2021
• [Memo to DOH Internal Offices] Acknowledgement of Comments_Concurrence on COVID-19 Vaccines Evaluation Framework
  February 15, 2021
• [Department Memorandum No. 2021- 0079] Endorsement of Topic Submissions from National Health Programs for HTA
  February 10, 2021
• [Department Memorandum No. 2021- 0079] Endorsement of Topic Submissions from National Health Programs for Health Technology Assessment
  February 10, 2021
• [DOH Department Circular] Submission of Data of COVID-19 Vaccines under EUA
  February 2, 2021

2020 Issuances

• [Memo to DOH Internal Offices] Consultation for COVID-19 Vaccines Evaluation Framework.
  December 28, 2020
• Memo on the Acceptance of Minor Inclusions in the Philippine National Formulary (PNF) for Health Technology Assessment (HTA) Following the PNF System for Drugs
  November 18, 2020
• Extension of Topic Nomination (Existing Health Technologies) for Health Technology Assessment until 10 November 2020
  September 21, 2020
• [Department Memorandum No. 2020-0366] Inclusion of 10- and 13-valent Pneumococcal Conjugate Vaccines (PCV) Multidose Preparation in the Philippine National Formulary
  August 14, 2020
• [Advisory] Consultative Meeting for Administrative Order 2020-0041
  March 11, 2020
• [Department Circular No. 2020-0011] Non-Acceptance of Requests for Exemption from the Philippine National Formulary
  January 23, 2020